MK-6194
6194-006
Phase 2 mab terminated
Quick answer
MK-6194 for Systemic Lupus Erythematosus is a Phase 2 program (mab) at Merck KGaA, Darmstadt, Germany with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Merck KGaA, Darmstadt, Germany
- Indication
- Systemic Lupus Erythematosus
- Phase
- Phase 2
- Modality
- mab
- Status
- terminated